超声诊断子宫内膜异位症和/或子宫腺肌症患者IVF/ICSI后的产科结局:前瞻性队列研究
该前瞻性队列纳入607例经IVF/ICSI后分娩的女性,按IDEA和修订MUSA超声标准诊断子宫内膜异位症和/或子宫腺肌症。结果显示,患病组早产、妊娠期高血压疾病、前置胎盘、产前出血及盆腔痛风险均显著高于无病组。
要点
- 子宫内膜异位症和/或子宫腺肌症患者早产风险升高(aRR 1.63,95%CI 1.06-2.49),主要为晚期早产。
- 前置胎盘风险显著增加(aRR 5.82,95%CI 2.32-14.6)。
- 妊娠期高血压疾病、产前出血及盆腔痛风险亦显著升高。
核心结论
- 子宫内膜异位症和/或子宫腺肌症患者经IVF/ICSI妊娠后,早产、妊娠期高血压疾病、前置胎盘、产前出血及盆腔痛风险较无病女性升高。
研究设计与样本
- 前瞻性观察性队列研究,纳入1035例接受最多三次连续IVF/ICSI治疗的女性,最终607例(91.1%)分娩且产科结局已知者纳入分析。
- 所有女性治疗前由专家行超声检查,依据IDEA和修订MUSA定义诊断子宫内膜异位症和/或子宫腺肌症。
- 主要结局为早产(妊娠未满37周分娩),采用改良Poisson回归计算调整相对风险。
主要发现
- 早产发生于27/144(18.9%)患病组 vs 53/463(11.4%)无病组,aRR 1.63(95%CI 1.06-2.49),P=0.025;仅晚期早产(孕34+0至36+6周)显著[21(16%)vs 37(8.0%),aRR 2.56(95%CI 1.26-5.21)]。
- 前置胎盘[13(9.0%)vs 7(1.5%),aRR 5.82(95%CI 2.32-14.6),P<0.001]、产前出血[17(11.8%)vs 30(6.5%),aRR 2.02(95%CI 1.19-3.41),P=0.009]、妊娠期高血压疾病[19(13.2%)vs 31(6.7%),aRR 2.26(95%CI 1.29-3.97),P=0.004]及盆腔痛[24(16.7%)vs 40(8.6%),aRR 1.91(95%CI 1.21-3.01),P=0.005]风险均显著增加。
- 羊水过少[10(6.9%)vs 15(3.3%),aRR 2.10(95%CI 0.98-4.48),P=0.055]及小于胎龄儿[22(15.3%)vs 45(9.7%),aRR 1.58(95%CI 0.98-2.53),P=0.059]风险有升高趋势但未达统计学显著。
- 剖宫产、妊娠期糖尿病、胎盘早剥及产后出血风险未见增加。
关键数值与推荐
- 子宫内膜异位症和/或子宫腺肌症诊断依据IDEA及修订MUSA超声定义。
- 早产定义为妊娠未满37周分娩;晚期早产为孕34+0至36+6周。
- 调整相对风险采用改良Poisson回归(稳健误差方差)计算。
临床怎么用
- 对子宫内膜异位症和/或子宫腺肌症经IVF/ICSI妊娠的女性,应告知早产、妊娠期高血压疾病、前置胎盘、产前出血及盆腔痛风险升高。
- 考虑针对这些风险制定个体化产前保健方案。
局限性
- 排除年龄≥40岁或BMI≥30 kg/m2女性,可能限制结果外推。
- 未评估浅表型腹膜子宫内膜异位症。
- 研究主要针对早产设计,次要结局可能把握度不足。
- 复合组以单纯子宫内膜异位症为主,仅子宫腺肌症者较少,混合分析可能稀释或掩盖疾病特异性关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Among women pregnant after IVF/ICSI, do obstetric outcomes differ for women diagnosed with endometriosis and/or adenomyosis according to definitions by International Deep Endometriosis (IDEA) and the revised Morphological Uterus Sonographic Assessment (MUSA) groups, compared to women without the disease? SUMMARY ANSWER: Women with endometriosis and/or adenomyosis have a higher risk of preterm birth, hypertensive disorders of pregnancy, placenta previa, antepartum hemorrhage, and pelvic pain, compared to women without. WHAT IS KNOWN ALREADY: Evidence regarding the impact of endometriosis and adenomyosis on obstetric outcomes remains inconsistent, largely due to heterogeneity in study design, diagnostic methods, disease criteria, and mode of conception. Therefore, clinical guidance on antenatal management for affected women remains limited. STUDY DESIGN, SIZE, DURATION: This was a prospective, observational cohort study of 1035 women who underwent up to three consecutive IVF/ICSI treatments at a university hospital. Published data suggest a preterm birth risk of 8-10% after IVF/ICSI without endometriosis, with higher rates in endometriosis and adenomyosis. Assuming 10% versus 20% preterm birth, 492 women were needed for 80% power. In total, 666 women gave birth to a child between January 2019 and April 2024. Of these, 607 (91.1%) women, for which the obstetric outcomes were known, were included in the study, while the remaining 59 (8.9%) were lost to follow-up. PARTICIPANTS/MATERIALS, SETTING, METHODS: Eligible for publicly funded IVF/ICSI treatments are non-smoking women aged 25 to ≤39 years, with a BMI of 18 to <30 kg/m2 and no previous children with the present partner. Women are entitled to up to three consecutive, publicly subsidized IVF/ICSI treatments, until the birth of the first child is achieved. All women underwent pretreatment ultrasound examination by an expert examiner, using the IDEA and revised MUSA definitions. Out of 607 included women, in total 144/607 (23.7%) women had endometriosis and/or adenomyosis. The primary outcome was preterm birth (delivery before completed 37 weeks gestation). Secondary outcomes included placenta previa, antepartum or postpartum hemorrhage, hypertensive disorders of pregnancy, gestational diabetes mellitus, caesarean section delivery, placental abruption, oligohydramnios, pelvic pain, and neonate small for gestational age, as well as outcomes stratified for women with different disease phenotypes. The adjusted relative risk for the different outcomes was calculated using modified Poisson regression analyses with robust error variances. MAIN RESULTS AND THE ROLE OF CHANCE: Preterm birth occurred in 27/144 (18.9%) women with endometriosis and/or adenomyosis compared to 53/463 (11.4%) in disease-free women, corresponding to an aRR 1.63 (95% CI, 1.06-2.49), P = 0.025. However, this was only significant for late preterm birth between gestational week 34 + 0-36 + 6 [21 (16%) vs 37 (8.0%), aRR 2.56 (95% CI, 1.26-5.21)] and not for earlier preterm birth. In addition, women with endometriosis and/or adenomyosis had an increased risk for placenta previa [13 (9.0%) vs 7 (1.5%), aRR 5.82 (95% CI, 2.32-14.6), P < 0.001], antepartum hemorrhage [17 (11.8%) vs 30 (6.5%), aRR 2.02 (95% CI, 1.19-3.41), P = 0.009], hypertensive disorders of pregnancy [19 (13.2%) vs 31 (6.7%), aRR 2.26 (95% CI, 1.29-3.97), P = 0.004] and pelvic pain [24 (16.7%) vs 40 (8.6), aRR 1.91 (95% CI, 1.21-3.01), P = 0.005] compared to disease-free women. There was a statistically non-significant tendency for an increased risk for developing oligohydramnios [10 (6.9%) vs 15 (3.3%), aRR 2.10, 95% CI, 0.98-4.48, P = 0.055] as well as delivering an SGA infant, [22 (15.3%) vs 45 (9.7%), aRR 1.58, 95% CI, 0.98-2.53, P = 0.059]. However, the risk for caesarean delivery, gestational diabetes mellitus, placental abruption, and postpartum hemorrhage was not increased. LIMITATIONS, REASONS FOR CAUTION: Excluding women aged ≥40 years or with a BMI ≥ 30 kg/m2 may limit the generalizability to other populations. The presence of superficial, peritoneal endometriosis was not accounted for. The study was powered for the primary outcome preterm birth in the total cohort and may have lacked sufficient power for the secondary outcomes. The composite endometriosis and/or adenomyosis group is dominated by isolated endometriosis, with relatively few women with combined disease. Women with adenomyosis only may represent a biologically and clinically distinct subgroup. Pooling them with endometriosis could potentially dilute or mask disease-specific associations. WIDER IMPLICATIONS OF THE FINDINGS: Our findings suggest that women with endometriosis and/or adenomyosis are at increased risk of common adverse pregnancy outcomes. Clinicians should recognize these risks when counseling affected women and consider tailored antenatal care. STUDY FUNDING/COMPETING INTEREST(S): This study was supported by regional research grants from Region Skåne, Sweden. There was no competing interest. TRIAL REGISTRATION NUMBER: Not applicable.
引用
- Alson S, Mattsson K, Sladkevicius P, et al. Obstetric outcomes after IVF/ICSI treatment in women with endometriosis and/or adenomyosis diagnosed by ultrasonography: a prospective cohort study. Hum Reprod. 2026. PMID: 42204604. doi:10.1093/humrep/deag084
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。